Chronic Disease Medicines & Devices

Chronic disease treatment connects recurring prescription demand with devices used in ongoing patient care, rather than dependence on technology infrastructure spending. The basket pairs diversified medicine franchises with diabetes and cardiovascular treatment specialists. Amgen's approaching earnings provide a near-term checkpoint, while strong recent drugmaker performance argues for selectivity rather than assuming defensive businesses are inexpensive. Launch basket (equal weight): LLY, ABBV, AMGN, MRK, JNJ, MDT, NVO, DXCM Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.